Metallothionein as a compensatory component prevents intermittent hypoxia-induced cardiomyopathy in mice

Toxicology and Applied Pharmacology

Volumn 277, Issue 1, 2014, Pages 58-66

  Yin, Xia ^a,b   Zhou, Shanshan ^a,b   Zheng, Yang ^a   Tan, Yi ^b,c   Kong, Maiying ^d   Wang, Bo ^b,e   Feng, Wenke ^b   Epstein, Paul N ^b   Cai, Jun ^b   Cai, Lu ^b,c  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^b University of Louisville School of Medicine   (United States)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF LOUISVILLE   (United States)

^e Inner Mongolia Forestry General Hospital   (China)

Author keywords

Cardiomyopathy; Intermittent hypoxia; Metallothionein; Obstructive sleep apnea; Oxidative damage

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; METALLOTHIONEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE LENGTH; CARDIOMYOPATHY; CHRONIC INTERMITTENT HYPOXIA; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPH; ECHOCARDIOGRAPHY; GENE DELETION; GENE OVEREXPRESSION; HEART EJECTION FRACTION; HEART FUNCTION; HEART INJURY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART WEIGHT; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; SLEEP DISORDERED BREATHING; THICKNESS; TIBIA; UPREGULATION;

CARDIOMYOPATHY; INTERMITTENT HYPOXIA; METALLOTHIONEIN; OBSTRUCTIVE SLEEP APNEA; OXIDATIVE DAMAGE;

ANIMALS; ANOXIA; CARDIOMYOPATHIES; MALE; METALLOTHIONEIN; MICE; MYOCARDIUM; OXIDATION-REDUCTION; OXIDATIVE STRESS; SLEEP APNEA, OBSTRUCTIVE;

EID: 84897950662     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.03.007     Document Type: Article

References (44)

1. Alchanatis M., Tourkohoriti G., Kosmas E.N., Panoutsopoulos G., Kakouros S., Papadima K., Gaga M., Jordanoglou J.B. Evidence for left ventricular dysfunction in patients with obstructive sleep apnoea syndrome. Eur. Respir. J. 2002, 20(5):1239-1245.
2. Baquet J.P., Barone-Rochette G., Tamisier R., Levy P., Pepin J.L. Mechanisms of cardiac dysfunction in obstructive sleep apnea. Nat. Rev. Cardiol. 2012, 9(12):679-688.
3. Bobillier-Chaumont S., Maupoil V., Berthelot A. Metallothionein induction in the liver, kidney, heart and aorta of cadmium and isoproterenol treated rats. J. Appl. Toxicol. 2006, 26(1):47-55.
4. Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic. Biol. Med. 2006, 41(6):851-861.
5. Cai L. Diabetic cardiomyopathy and its prevention by metallothionein: experimental evidence, possible mechanisms and clinical implications. Curr. Med. Chem. 2007, 14(20):2193-2203.
6. Cai L., Satoh M., Tohyama C., Cherian M.G. Metallothionein in radiation exposure: its induction and protective role. Toxicology 1999, 132(2-3):85-98.
7. Cai L., Wang J., Li Y., Sun X., Wang L., Zhou Z., Kang Y.J. Inhibition of superoxide generation and associated nitrosative damage is involved in metallothionein prevention of diabetic cardiomyopathy. Diabetes 2005, 54(6):1829-1837.
8. Cai L., Wang Y., Zhou G., Chen T., Song Y., Li X., Kang Y.J. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 2006, 48(8):1688-1697.
9. Cai J., Tuong C.M., Gozal D. A neonatal mouse model of intermittent hypoxia associated with features of apnea in premature infants. Respir. Physiol. Neurobiol. 2011, 178(2):210-217.
10. Cai J., Tuong C.M., Zhang Y., Shields C.B., Guo G., Fu H., Gozal D. Mouse intermittent hypoxia mimicking apnoea of prematurity: effects on myelinogenesis and axonal maturation. J. Pathol. 2012, 226(3):495-508.
11. Campen M.J., Shimoda L.A., O'Donnell C.P. Acute and chronic cardiovascular effects of intermittent hypoxia in C57BL/6J mice. J. Appl. Physiol. 2005, 99(5):2028-2035. (1985).
12. Chen Y., Saari J.T., Kang Y.J. Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radic. Biol. Med. 1994, 17(6):529-536.
13. Chen L.M., Kuo W.W., Yang J.J., Wang S.G., Yeh Y.L., Tsai F.J., Ho Y.J., Chang M.H., Huang C.Y., Lee S.D. Eccentric cardiac hypertrophy was induced by long-term intermittent hypoxia in rats. Exp. Physiol. 2007, 92(2):409-416.
14. Dubé A., Harrisson J.F., Saint-Gelais G., Séguin C. Hypoxia acts through multiple signaling pathways to induce metallothionein transactivation by the metal-responsive transcription factor-1 (MTF-1). Biochem. Cell Biol. 2011, 89(6):562-577. (Dec).
15. Fung J.W., Li T.S., Choy D.K., Yip G.W., Ko F.W., Sanderson J.E., Hui D.S.C. Severe obstructive sleep apnea is associated with left ventricular diastolic dysfunction. Chest 2002, 121:422-429.
16. Greenberg H., Ye X., Wilson D., Htoo A.K., Hendersen T., Liu S.F. Chronic intermittent hypoxia activates nuclear factor-kappaB in cardiovascular tissues in vivo. Biochem. Biophys. Res. Commun. 2006, 343(2):591-596.
17. Hedeker D., Gibbons R.D. Longitudinal Data Analysis 2006, Wiley & Sons, Inc., Hoboken, New Jersey, USA.
18. Jun J., Savransky V., Nanayakkara A., Bevans S., Li J., Smith P.L., Polotsky V.Y. Intermittent hypoxia has organ-specific effects on oxidative stress. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295(4):R1274-R1281.
19. Kang Y.J. The antioxidant function of metallothionein in the heart. Proc. Soc. Exp. Biol. Med. 1999, 222(3):263-273.
20. Khayat R., Patt B., Hayes D. Obstructive sleep apnea: the new cardiovascular disease. Part I: Obstructive sleep apnea and the pathogenesis of vascular disease. Heart Fail. Rev. 2009, 14(3):143-153.
21. Kojima I., Tanaka T., Inagi R., Nishi H., Aburatani H., Kato H., Miyata T., Fujita T., Nangaku M. Metallothionein is upregulated by hypoxia and stabilizes hypoxia-inducible factor in the kidney. Kidney Int. 2009, 75(3):268-277.
22. Kost K.M. Endoscopic percutaneous dilatational tracheotomy: a prospective evaluation of 500 consecutive cases. Laryngoscope 2005, 115(10 Pt 2):1-30.
23. KraicZi H., Caidahl K., Samuelsson A., Peker Y., Hedner J. Impairment of vascular endothelial function and left ventricular filling: association with the severity of apnea-induced hypoxemia during sleep. Chest 2001, 119:1085-1091.
24. Little R.C., Stroup W.W., Freund R.J. SAS for Linear Models 2002, SAS Institute Inc., Cary, NC, USA.
25. Malec V., Gottschald O.R., Li S., Rose F., Seeger W., Hänze J. HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. Free Radic. Biol. Med. 2010, 48(12):1626-1635.
26. Mukhopadhyay P., Rajesh M., Batkai S., Kashiwaya Y., Hasko G., Liaudet L., Szabo C., Pacher P. Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro. Am. J. Physiol. Heart Circ. Physiol. 2009, 296(5):H1466-H1483.
27. Murphy B.J., Kimura T., Sato B.G., Shi Y., Andrews G.K. Metallothionein induction by hypoxia involves cooperative interactions between metal-responsive transcription factor-1 and hypoxia-inducible transcription factor-1alpha. Mol. Cancer Res. 2008, 6(3):483-490.
28. Murry C.E., Jennings R.B., Reimer K.A. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986, 74(5):1124-1136.
29. Naganuma A., Satoh M., Imura N. Specific reduction of toxic side effects of adriamycin by induction of metallothionein in mice. Jpn. J. Cancer Res. 1988, 79(3):406-411.
30. Odom A.L., Hatwig C.A., Stanley J.S., Benson A.M. Biochemical determinants of Adriamycin toxicity in mouse liver, heart and intestine. Biochem. Pharmacol. 1992, 43(4):831-836.
31. Patil S.P., Schneider H., Schwartz A.R., Smith P.L. Adult obstructive sleep apnea: pathophysiology and diagnosis. Chest 2007, 132(1):325-337.
32. Pinto J.M., Garpestad E., Weiss J.W., Bergau D.M., Kirby D.A. Hemodynamic changes associated with obstructive sleep apnea followed by arousal in a porcine model. J Appl Physiol 1993, 75(4):1439-1443. (1985).
33. Punjabi N.M. The epidemiology of adult obstructive sleep apnea. Proc. Am. Thorac. Soc. 2008, 5(2):136-143.
34. Rosamond W., Flegal K., Friday G., Furie K., Go A., Greenlund K., Haase N., Ho M., Howard V., Kissela B., Kittner S., Lloyd-Jones D., McDermott M., Meigs J., Moy C., Nichol G., O'Donnell C.J., Roger V., Rumsfeld J., Sorlie P., Steinberger J., Thom T., Wasserthiel-Smoller S., Hong Y. Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2007, 115(5):e69-e171.
35. Sato M., Sasaki M., Hojo H. Tissue specific induction of metallothionein synthesis by tumor necrosis factor-alpha. Res. Commun. Chem. Pathol. Pharmacol. 1992, 75(2):159-172.
36. Satoh M., Naganuma A., Imura N. Modulation of adriamycin toxicity by tissue-specific induction of metallothionein synthesis in mice. Life Sci. 2000, 67(6):627-634.
37. Singh S.B., Selvamurthy W. Effect of intermittent chronic exposure to hypoxia on feeding behaviour of rats. Int. J. Biometeorol. 1993, 37(4):200-202.
38. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005, 85(3):1093-1129.
39. Wang J., Song Y., Elsherif L., Song Z., Zhou G., Prabhu S.D., Saari J.T., Cai L. Cardiac metallothionein induction plays the major role in the prevention of diabetic cardiomyopathy by zinc supplementation. Circulation 2006, 113(4):544-554.
40. Williams A.L., Chen L., Scharf S.M. Effects of allopurinol on cardiac function and oxidant stress in chronic intermittent hypoxia. Sleep Breath. 2010, 14(1):51-57.
41. Yin X., Zheng Y., Liu Q., Cai J., Cai L. Cardiac response to chronic intermittent hypoxia with a transition from adaptation to maladaptation: the role of hydrogen peroxide. Oxid. Med. Cell. Longev. 2012, 2012:569520.
42. Young T., Peppard P.E., Gottlieb D.J. Epidemiology of obstructive sleep apnea: a population health perspective. Am. J. Respir. Crit. Care Med. 2002, 165(9):1217-1239.
43. Yuan G., Nanduri J., Khan S., Semenza G.L., Prabhakar N.R. Induction of HIF-1alpha expression by intermittent hypoxia: involvement of NADPH oxidase, Ca2+ signaling, prolyl hydroxylases, and mTOR. J. Cell. Physiol. 2008, 217(3):674-685.
44. Zhou G., Li X., Hein D.W., Xiang X., Marshall J.P., Prabhu S.D., Cai L. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J. Am. Coll. Cardiol. 2008, 52(8):655-666.